Annogen introduces AIM™ service

Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel)

Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its proprietary SuRE™ barcoding strategy and previously established protocols, Annogen has now scaled a gene-insertion and expression mapping strategy to unprecedented numbers.

AIM™ applications

  • Genetic engineering T cells, NK cells, B cells
    • E.g. Expression upon T-cell activation or in specific lineage
  • Production lines for stable expression
    • E.g. CHO sites for maximum expression level
  • Production lines for induced expression
    • E.g. HEK293T sites for induced expression of Rep protein
  • Reporter lines for drug screens…
    • E.g. Fluorescence upon inflammation, proliferation, apoptosis, …

Example of AIM™ screen in Jurkat cells

Integrations Heatmap N=310807

Identify loci that are only active upon T-cell activation

Conclusion

300-fold induction upon Jurkat stimulation with lonomycin and PMA

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

The first patient dosing in VectorY Therapeutics’ PIONEER-ALS trial marks a definitive shift in gene therapy, moving past the “conservative” reliance on blunt viral promoters and the “digital guesses” of AI. While many rely on algorithms built from incomplete and insensitive data, VTx-002 is powered by an Annogen genome-derived promoter discovered through rigorous, large-scale experimental validation. This milestone proves that true therapeutic precision isn’t predicted in a black box—it is found by interrogating the genome directly to deliver the biological truth required for the clinic.

Technology

 

Solutions

 

Annogen